Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials

Stauffer, Virginia; Ascher-Svanum, Haya; Lin Liu; Ball, Tamara; Conley, Robert
January 2009
BMC Psychiatry;2009, Vol. 9, Special section p1
Academic Journal
Background: How long an antipsychotic is effective in maintaining response is important in choosing the correct treatment for people with schizophrenia. This post-hoc analysis describes maintenance of response over 24 or 28 weeks in people treated for schizophrenia with olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole. Methods: This was a post-hoc analysis using data from 5 double-blind, randomized, comparative trials of 24 or 28 weeks duration in which olanzapine was compared to risperidone (1 study; N = 339), quetiapine (1 study; N = 346), ziprasidone (2 studies; N = 548 and 394) or aripiprazole (1 study; N = 566) for treatment of schizophrenia. For each study, time to loss of response in patients who met criteria for response at Week 8 and the proportion of patients who lost response following Week 8 were compared by treatment group. The number needed to treat (NNT) with olanzapine rather than comparator to avoid loss of one additional responder over 24 or 28 weeks of treatment was calculated for each study. Results: Time maintained in response was significantly longer (p < .05) for olanzapine compared to risperidone, quetiapine, and ziprasidone. Olanzapine did not significantly differ from aripiprazole. The proportion of patients who lost response was significantly lower for olanzapine versus risperidone, quetiapine, and ziprasidone (p < .05). NNTs to avoid one additional patient with loss of response with olanzapine versus risperidone, quetiapine and ziprasidone were favourable, ranging from 5 to 9. Conclusion: During 24 and 28 weeks of treatment, the antipsychotics studied differed in the time that treated patients with schizophrenia remained in response and the proportion of patients who lost response. Olanzapine treatment resulted in a consistent and statistically significant advantage in maintenance of response compared to treatment with risperidone, quetiapine and ziprasidone; but not compared to treatment with aripiprazole.


Related Articles

  • Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Souza, F. G. M.; Goodwin, G. M.; Souza, F G // British Journal of Psychiatry;May91, Vol. 158, p666 

    Meta-analysis was used to establish the efficacy of lithium in acute treatment and prophylaxis of depressive illness from existing published clinical trials. Effect sizes were measured by the odds ratio using the Mantel-Haenszel method and the Pearson product-moment correlation coefficient. Some...

  • No Influence of DTNBP1 Polymorphisms on the Response to Aripiprazole. Chi-Un Pae; Chiesa, Alberto; Mandelli, Laura; Serretti, Alessandro // Neuropsychobiology;2010, Vol. 62 Issue 4, p245 

    Aims: The aim of the present study was to investigate pos- sible influences of a panel of markers in the dysbindin gene DTNBP1 (rs3213207, rs1011313, rs2005976, rs760761 and rs2619522) on the clinical outcome and side effects associated to the treatment with aripiprazole in schizophrenic...

  • BioLineRx to Present Data from the Successfully Completed Phase IIb Trial of BL-1020 at European Conference on Schizophrenia Research.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p497 

    The article reports on the announcement of BioLineRx Ltd. on the release of data from the completed phase IIb trial of GABA-enhanced antipsychotic BL-1020 to be presented at the3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany. The trial has demonstrated the...

  • Oestrogen -- a new treatment approach for schizophrenia? Kulkarni, Jayashri // Medical Journal of Australia;2/16/2009 Supplement, pS37 

    The article explores the potential of oestrogen protection as a treatment approach for schizophrenia. The effectiveness of oestrogen as a protection against onset of the illness has been proven by cited epidemiological, clinical, and animal studies. Studies on the impact of adding oestradiol to...

  • In Vivo Pharmacological Evaluations of Novel Olanzapine Analogues in Rats: A Potential New Avenue for the Treatment of Schizophrenia. Jafari, Somayeh; Huang, Xu-Feng; Andrews, Jessica L.; Fernandez-Enright, Francesca // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Olanzapine (Olz) is one of the most effective antipsychotic drugs commonly used for treating schizophrenia. Unfortunately, Olz administration is associated with severe weight gain and metabolic disturbances. Both patients and clinicians are highly interested in the development of new...

  • A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials. Molenberghs, Geert; Burzykowski, Tomasz; Alonso, Ariel; Assam, Pryseley; Tilahun, Abel; Buyse, Marc // Statistical Methods in Medical Research;Jun2010, Vol. 19 Issue 3, p205 

    For a number of reasons, surrogate endpoints are considered instead of the so-called true endpoint in clinical studies, especially when such endpoints can be measured earlier, and/or with less burden for patient and experimenter. Surrogate endpoints may occur more frequently than their standard...

  • Monitoring psychosis in general practice: a controlled trial. Nazareth, Irwin; King, Michael; See Tai, Sharon; Nazareth, I; King, M; Tai, S S // British Journal of Psychiatry;Oct96, Vol. 169, p475 

    Background: This trial evaluated the feasibility, acceptability and effectiveness of a structured approach to the management of schizophrenia in general practice.Method: All patients with non-affective psychosis (mainly schizophrenia) in four inner-city general...

  • Peer Review of "Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol". Peuskens, J. // British Journal of Psychiatry;Jun95, Vol. 166, p727 

    The article presents a peer review of the study "Risperidone in the Treatment of Patients with Chronic Schizophrenia: A Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol," by J. Peuskens. The assessments presents two reviewers' comments on both the original and...

  • Atypical antipsychotics appear to be effective for only few off-label uses.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p179 

    The article presents information regarding the effectivity of atypical antipsychotic medications indicating that it could only be for a few off-label conditions and that the benefits and harms of these medications for these uses vary.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics